St. Jude Will Tap Heart Valve Sales Reps For VSI Initial Anastomosis Product
This article was originally published in The Gray Sheet
Executive Summary
St. Jude's strategy to capitalize long-term on its entry into the coronary artery treatment market through the $100 mil. acquisition of Vascular Science, Inc. will draw on established relationships between clinicians and the firm's Heart Valve division (cardiac surgeons) and the Daig electrophysiology division (interventionists).